Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2014  |  Volume : 10  |  Issue : 4  |  Page : 853-858

An overview of doxorubicin formulations in cancer therapy

Department of Research and Development, Bharat Serums and Vaccines Limited, R and D Centre, Mumbai, Maharashtra, India

Date of Web Publication9-Jan-2015

Correspondence Address:
Sangeeta Rivankar
Bharat Serums and Vaccines Limited, R and D Centre, DIL Complex, Near Tatwagyan Vidyapeeth, Ghodbunder Road, Thane West, Mumbai - 400 610, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.139267

Rights and Permissions
 > Abstract 

The burden of cancer is continuously increasing, and is rapidly becoming a global pandemic. The first liposomal encapsulated anticancer drug which received clinical approval against malignancies including solid tumours, transplantable leukemias and lymphomas was Doxorubicin HCl. This review is aimed at providing an overview of doxorubicin in cancer therapy. Pegylated liposomal doxorubicin has a polyethylene glycol (PEG) layer around doxorubicin-containing liposome as the result of a process known as pegylation. Non-pegylated liposomal doxorubicin (NPLD) was developed to overcome the drawbacks associated with previous formulations. Nudoxa; (NPLD) with its unique drug delivery system offers the benefit of pegylated liposomal doxorubicin without hand foot syndrome as the major side effect. Future studies will be directed towards estimating the costs of treatment with the novel liposomal doxorubicin formulations in order to assess their widespread use and robustness in treating patients with cancer.

 > Abstract in Chinese 


Keywords: Liposomal, nonpegylated, nudoxa, pegylated

How to cite this article:
Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Can Res Ther 2014;10:853-8

How to cite this URL:
Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Can Res Ther [serial online] 2014 [cited 2022 Jul 7];10:853-8. Available from: https://www.cancerjournal.net/text.asp?2014/10/4/853/139267

 > Introduction Top

Cancer is a leading cause of morbidity and mortality worldwide. It is estimated that there will be 13.1 million deaths due to cancer in 2030. [1] Anthracyclines, especially doxorubicin, have been the mainstay of cancer therapy since long. Despite its broad-spectrum antineoplastic activity [Table 1], adverse events [Table 2], particularly cardiotoxicity, has limited the use of conventional doxorubicin in clinical practice. [2] This was especially so in patients with advanced disease requiring dose escalation. [3]
Table 1: The rapeutic uses of doxorubicin

Click here to view
Table 2: Adverse effects associated with doxorubicin

Click here to view

Doxorubicin hydrochloride (HCl) liposomal injection was the first liposomal encapsulated anticancer drug to receive clinical approval and has activity against a number of malignancies including solid tumors, transplantable leukemias, and lymphomas. [4]

Previous clinical studies have focused on the lower toxicity and better tolerability of liposomal anticancer drugs. [4] However, in recent years, research has focused on developing novel liposomal formulations. This review is aimed at providing an overview of doxorubicin in cancer therapy.

 > History of doxorubicin Top

The quest for anticancer compounds from soil-based microorganisms began in the 1950s. A new strain of Streptomyces peucetius, which produced a bright red pigment, was isolated, and an antibiotic was produced from this bacterium that was found to have good activity against mouse tumors. The new compound was named daunorubicin and was used successfully in the treatment of acute leukemia and lymphoma [5],[6] . However, by 1967, it was recognized that daunorubicin could produce fatal cardiac toxicity. [7]

Researches made genetic modifications to the Streptomyces spp. to produce a compound, Adriamycin, which was later called doxorubicin. Though doxorubicin had a higher therapeutic index cardiotoxicity continued to be a major problem. These compounds have been prototypes for subsequent research and today there are approximately more than 2000 known analogs of doxorubicin.

 > Mechanism of action of doxorubicin Top

The exact mechanism of action of doxorubicin is complex and still unclear. Doxorubicin interacts with the DNA by intercalation thus, inhibiting macromolecular biosynthesis. [8],[9] This further inhibits the progression of the enzyme topoisomerase II, and relaxes supercoils in DNA for transcription. Doxorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication [Figure 1]. Another mechanism of doxorubicin HCl is its ability to generate free radicals that induce DNA and cell membrane damage.
Figure 1: Mechanism of action of doxorubicin

Click here to view

 > Doxorubicin in cancer therapy Top

Doxorubicin is most commonly used to treat cancers of the bladder, breast, stomach, lung, ovaries, thyroid, soft tissue sarcoma, multiple myeloma, and Hodgkin's lymphoma. The commonly used doxorubicin-containing regimens may include Adriamycin, cyclophosphamide (AC), Taxotere, AC, Adriamycin, bleomycin, vinblastine, dacarbazine, bleomycin, etoposide, AC, vincristine, procarbazine, and prednisone, cyclophosphamide, Adriamycin, vincristine, prednisone and 5-fluorouracil, AC. Doxil is mainly used for the treatment of ovarian cancer where it has progressed or recurred after platinum-based chemotherapy, or for the treatment of AIDS-related Kaposi's sarcoma. [10]

 > Cardiotoxicity associated with conventional doxorubicin Top

The cardiotoxicity associated with conventional doxorubicin is broadly classified as either acute or chronic. [11],[12],[13] It is a major concern during therapy as it may be dose-limiting. Risk factors that may increase the occurrence of cardiotoxicity include previous or current heart disease, extremes in age, race, exposure to irradiation in the mediastinal region and the cumulative dose of doxorubicin received. Patients with acute doxorubicin-induced cardiotoxicity usually present with rhythm disturbances, abnormal electrocardiographic changes, and acute, but reversible, reductions in left-ventricular ejection fraction. In general, these symptoms occur within 24 h of infusion, are self-limiting, and do not appear to increase the risk of future cardiac events. Cardiotoxicity, a consequence of conventional doxorubicin treatment manifests as a chronic complication, which ultimately results in congestive cardiomyopathy. Such toxicity has been shown to correlate with peak plasma doxorubicin concentrations, as well as with the lifetime cumulative dose administered. [14],[15] Historically, cardiomyopathy has rarely been observed with cumulative doses of conventional doxorubicin below 450 mg/m 2 ; however, studies suggest that doxorubicin-induced congestive heart failure (CHF) may occur at lower-doses and with greater frequency than previously noted. [16],[17] Von Hoff et al.[16] reported incidence of conventional doxorubicin-induced CHF of approximately 3% at cumulative dose of 400 mg/m 2 , increasing to 7% at 550 mg/m 2 and to 18% at 700 mg/m 2 .

 > Rationale for the development of novel doxorubicin formulations Top

Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the development of novel anthracycline analogs, the use of low-dose, prolonged, continuous infusion schedules; co-administration with the cardioprotective agent dexrazoxane; and the use of liposomal encapsulation technology. [12],[18],[19]

The therapy-limiting toxicity for this drug is cardiomyopathy, which may lead to CHF and death. An approach to ameliorating doxorubicin-related toxicity is to use drug carriers, which engender a change in the pharmacological distribution of the drug, resulting in reduced drug levels in the heart. Examples of these carrier systems include lipid-based (liposome) formulations that effect a beneficial change in doxorubicin. Liposomal encapsulation represents the most successful strategy to date for increasing the therapeutic index of conventional anthracyclines. Liposomal drug-delivery systems have been studied extensively to increase the therapeutic index of chemotherapy. The development of liposomal anthracyclines was based on the rationale that liposomes cannot escape the vascular space in areas with tight capillary junctions (heart muscle) but can leave the circulation in tissues and organs lined with cells that are not tightly joined (tumor cells). [20] Thus, liposomal encapsulation results in the preferential concentration of anthracyclines in tumor tissue, while limiting exposure in those sites most frequently associated with conventional anthracycline toxicity, such as the myocardium.

 > Liposomal formulations of doxorubicin Top

Due to the side-effects of conventional doxorubicin therapy, a need for development of liposomal formulation with equal efficacy and less side-effects arose. One of the main advantages of using liposomes as a delivery system is that the phospholipids used to form these vesicles are extracted from natural sources such as egg yolks or soybean and hence they are safe in the body. In addition, the degree of saturation of phospholipid bilayer can be modified to alter the drug release rate.

Liposomes, composed of natural phospholipids mixed with varying amounts of cholesterol are removed from circulation by the reticuloendothelial system (RES) within a few minutes to a few hours, subsequent to the acquisition of opsonins from plasma. Because of this short circulation half-life, the use of conventional liposomes has limited clinical applications.

 > Pegylated liposomal formulations of doxorubicin Top

The fact that some polymers, such as polyethylene glycol (PEG), ganglioside, and cerebroside sulfate are able to inhibit opsonization of the liposomes by plasma proteins and increase the half-life of liposomal drugs has renewed activity in the area of liposomal drug-delivery systems. Prolonged circulation of liposomes has been linked to better therapeutic efficacy of liposomal anthracyclines, possibly related to increased accumulation of drug loaded liposomes in tumor tissue.

A further advancement in this line of treatment was the pegylated-liposomal doxorubicin (such as Doxil® /Caelyx® ), a unique form of liposomal doxorubicin, in which the liposomes were coated with PEG in a process known as pegylation. This prevents drug uptake by the RES, thereby prolonging the circulation time (half-life: 3-4 days [21] vs. 30 h for conventional doxorubicin [22] ) beyond that of conventional liposomes and enabling the drug to remain encapsulated until it reaches the tumor site. [23],[24]

Doxil® is approved by the Food and Drug Administration (FDA) for treatment of ovarian cancer after failure of first line platinum-based chemotherapy and multiple myeloma. Outside the United States, Doxil® is known as Caelyx® and is marketed by Janssen. [25] However, there is some evidence that raises doubts on the benefits of pegylation in cancer treatment. PEG is a large molecule and its presence on the liposomal surface may decrease the interactions of liposomes with cells and impede the entry of liposomes into the tumor tissue. [26] This may possibly reduce the accumulation of liposomal drugs in the tumor tissue. A study assessing the accumulation of liposomal doxorubicin in murine Lewis lung carcinoma showed that benefits with PEG liposomal doxorubicin, such as increased blood levels and circulation time may be of little advantage when compared to maximizing drug accumulation in tumors. [27]

However, pegylated-liposomal doxorubicins cause dose-limiting hand-foot syndrome (HFS) (palmar-plantar erythrodysesthesia) characterized by skin eruptions on the palms of the hand and/or soles of the feet, leading to interruption in therapy by at least 2 weeks and decrease in subsequent dosage by 25% (Doxil Product Information Leaflet). The incidence of HFS has been observed in approximately 50% of patients dosed at 50 mg/m 2 (Doxil Product Information leaflet).

Though Caelyx® /Doxil® (pegylated liposomal doxorubicin) has high affinity for the skin and a very long circulation time, a major limitation is dose-limiting HFS (palmar-plantar erythrodysesthesia). [28]

 > Nonpegylated liposomal formulations of doxorubicin Top

There remains a need for stable, long circulating liposomes that do not cause such deleterious effects such as the HFS. The new variant of liposomal doxorubicin, nonpegylated liposomal doxorubicin (NPLD), has a unique drug-delivery system, and provides a breakthrough in cancer therapy by offering the benefits of pegylated-liposomal doxorubicin without its major side-effects such as HFS.

Nonpegylated liposomal doxorubicin injection provides a better safety profile than not only conventional doxorubicin, but also Doxil® /Caelyx® . NPLD not only reduces the cardiac toxicity associated with doxorubicin, but also the dose-limiting toxicity associated with the use of Doxil® /Caelyx® , such as HFS. This is achieved by a combination of (1) specific composition and (2) a unique manufacturing process (both which have been patented) of the NPLD's liposome, which gives it the desired physicochemical properties.

The NPLDs have an increased circulation time and less cardiotoxicity as compared with conventional doxorubicin. Since NPLDs do not have PEG coating, they are not associated with the painful HFS, which is a dose-limiting adverse event with PEG-doxorubicin.

Myocet® is a NPLD manufactured by Enzon Pharmaceuticals for Cephalon in Europe and for Sopherion Therapeutics in the United States and Canada. [29] Myocet® is approved in Europe and Canada for treatment of metastatic breast cancer in combination with cyclophosphamide. [30] However, it is under the process for the US FDA approval. Three Phase III trials in breast cancer evaluated Myocet® in comparison with standard doxorubicin and epirubicin. Compared to standard doxorubicin, Myocet® demonstrated less cardiotoxicity with no loss of efficacy. Equal doses of epirubicin and Myocet® were as effective with no significant difference in cardiotoxicity. Another limitation of Myocet® is related to its administration which is presented as a three-vial system; Myocet doxorubicin HCl, Myocet liposomes and Myocet buffer. In addition, a small amount of 0.9% sodium chloride for injection is needed, which is not provided in the package. The constituted product is a liposome-encapsulated doxorubicin-citrate complex. [31] Further, the high cost of Myocet® has been a hindrance in its widespread use. This has been a limitation in its robust assessment within the treatment pathway for advanced cancers.

Nudoxa® (NPLD) with its unique drug-delivery system is a breakthrough in cancer therapy as it offers the benefit of pegylated liposomal doxorubicin without its major side-effects like HFS. Further, it decreased the toxicity and other adverse events such as nausea, vomiting, and alopecia. Nudoxa® was jointly developed by Zydus and Bharat Serums and Vaccines Pvt. Limited Nudoxa® is being used as a chemotherapy drug to treat various cancers, such as breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. The formulation uses distearoyl-phosphatidylcholine, a phospholipid with high phase transition temperature, which increases the retention of the liposomal content. This allows the doxorubicin HCl liposomes to circulate for prolonged periods in the bloodstream. Liposomes are small enough (average diameter of approximately 100 nm) to pass intact (extravasate) through the defective blood vessels present in the tumors. The liposomal covering helps the drug from escaping into the body's immune system thereby enabling the drug to reach malignant cells. This results in reduction of harmful side-effects owing to minimized distribution of the drug to nontargeted tissues. The preclinical studies were aimed at comparing Nudoxa® with PEG liposomal doxorubicin and conventional doxorubicin (data on file). Nudoxa® has demonstrated favorable toxicity profile in animal models. Further, it offers an advantage over pegylated liposomal doxorubicin due to the absence of HFS. Maximum tolerated dose for Nudoxa® has been established at 70 mg/m 2 in Phase I clinical trials (data on file).

Nudoxa® was launched in the Indian market in 2008 and is being used as a chemotherapy drug to treat various cancers, particularly, breast cancer, ovarian cancer and AIDS-related Kaposi sarcoma. A Phase II/III open label multicentric randomized trial determined the safety and efficacy of Nudoxa® at two different dose levels as compared to doxorubicin in patients with metastatic breast cancer. The trial reported that Nudoxa® at 70 mg/m 2 was as efficacious as conventional doxorubicin with a better safety profile (CTRI/2009/091/1000795).

 > Other novel formulations of doxorubicin Top

Stealth liposomes have gained an important place in cancer chemotherapy, but still these liposomes are modulated in terms of their selectivity for tumors by attachment of ligands. [32] Antibody coated liposome (immunoliposomes) are extensively studied where either an antibody is attached directly to liposome phospholipid head group or to the terminus of PEG polymer. [33] Temperature sensitive liposomes are also fabricated for tumor targeting. Similarly, acid triggered, enzyme triggered and light triggered release are being studied for delivery of doxorubicin. Other case of active targeting are sulfatide-mediated liposome [34] and folate receptor targeting. [35] Block co-polymers of poly (ethylene oxide)-poly (propylene oxide) block copolymers (pluronics) have also being developed for doxorubicin. Hydroxyapatite implants containing doxorubicin have been developed and tested in in vivo model for osteogenic sarcoma. [36] Thermosensitive poly (organophosphazenes) hydrogels containing doxorubicin have also been studied. The release of loaded doxorubicin from the polymer hydrogel was significantly sustained over 20 days. Oral delivery of microgels composed of pluronics was found to be active against Caco-2 cells. [37] Biological particles like resealed erythrocytes and bacterial ghosts are being explored for the delivery of doxorubicin are also proving to be quite effective. [38] Nanoparticles prepared using polybutylcyanoacrylate as delivery system for doxorubicin to target liver cancer have been studied. [39] The findings suggested that drug was released slowly in liver during detection period in treatment groups. Nanoparticles in range of 100-150 nm diameter range had the best liver targeting characteristics. It also decreased doxorubicin distribution in other tissues such as heart, kidney, and lung. Poly (butylcyanoacrylate) nanoparticles coated with polysorbate 80 considerably enhance the antitumor effect of doxorubicin against an intracranial glioblastoma in rats. [40]

Doxorubicin-loaded polymer-lipid hybrid nanoparticles were formulated and evaluated in a murine solid tumor model. [41] A new bioadhesive drug-delivery system, poly (d, l-lactide-co-glycolide/montmorillonite nanoparticles were developed for oral delivery of paclitaxel. Such a novel formulation is expected to possess extended residence time in the gastrointestinal tract, which promotes oral delivery of paclitaxel. [42]

Among the novel formulations, only the liposomal doxorubicin formulations have been extensively studied and explored in clinical trials in patients with different stages of cancer.

 > Conclusion Top

Conventional doxorubicin has been a mainstay of treatment for breast and ovarian cancers. Although the use of conventional doxorubicin has been somewhat limited by its adverse effects, recent efforts have markedly improved its safety and tolerability. Until date, the most successful strategy for improving the therapeutic index of conventional doxorubicin formulations has been liposomal encapsulation, which results in preferential accumulation of drug within the tumor site to maximize efficacy and minimize toxicity. Pegylated liposomal doxorubicin has demonstrated efficacy in ovarian cancer patients who have failed platinum and paclitaxel therapies, as well as in metastatic breast cancer. However, dose-limiting HFS limits its usage. Nudoxa® is a NPLD, in which doxorubicin is confined in nonpegylated liposomes. Safety and efficacy of Nudoxa® has been established in several preclinical studies (data on file). Currently Nudoxa® is being studied in clinical trials to establish its safety and efficacy in different types of cancers. The early results show that Nudoxa® is as efficacious as conventional doxorubicin with a better safety profile. This may present an improved treatment regimen for late stage cancer patients.

With established efficacy and safety profiles, future studies will hopefully be directed toward estimating the costs of treatment with the novel liposomal doxorubicin formulations in order to assess their widespread use and robustness in treating patients with cancer.

 > References Top

GLOBOCAN (IARC) Section of Cancer Information. Available from: http://www.globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900. [Last accessed on 2012 May 10].  Back to cited text no. 1
Thigpen JT. Innovations in anthracycline therapy: Overview. Commun Oncol 2005;2:3-7.  Back to cited text no. 2
Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 2004;100:2052-63.  Back to cited text no. 3
Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012;17:160-6.  Back to cited text no. 4
Brockmann H. Anthracyclinones and anthracyclines. (Rhodomycinone, pyrromycinone and their glycosides). Fortschr Chem Org Naturst 1963;21:121-82.  Back to cited text no. 5
Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969;11:1101-10.  Back to cited text no. 6
Available from: http://www.usbio.net/misc/doxorubicin. [Last accessed on 2014 Apr 28].  Back to cited text no. 7
Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994;45:649-56.  Back to cited text no. 8
Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 1976;36:2891-5.  Back to cited text no. 9
Available from: http://www.cancer.gov/cancertopics/druginfo/fda-doxorubicin-HCL-liposome. [Last accessed on 2013 Oct 24].  Back to cited text no. 10
Balmer C, Valley AW. Basic principles of cancer treatment and cancer chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 3 rd ed. Stamford, Conn: Appleton and Lange; 1997. p. 2403-65.  Back to cited text no. 11
Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: Changing toxicity profiles. Drug Saf 2001;24:903-20.  Back to cited text no. 12
Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention. Drug Saf 2000;22:263-302.  Back to cited text no. 13
Maluf FC, Spriggs D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol 2002;85:18-31.  Back to cited text no. 14
Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54:1-7.  Back to cited text no. 15
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.  Back to cited text no. 16
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-79.  Back to cited text no. 17
Birtle AJ. Anthracyclines and cardiotoxicity. Clin Oncol (R Coll Radiol) 2000;12:146-52.  Back to cited text no. 18
Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999;3:145-59.  Back to cited text no. 19
Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target 1996;4:129-40.  Back to cited text no. 20
Hilger RA, Richly H, Grubert M, Oberhoff C, Strumberg D, Scheulen ME, et al. Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil. Int J Clin Pharmacol Ther 2005;43:588-9.  Back to cited text no. 21
Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 1991;28:302-7.  Back to cited text no. 22
Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54 Suppl 4:15-21.  Back to cited text no. 23
Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.  Back to cited text no. 24
Available from: http://www.doxil.com/. [Last accessed 2012 May 14].  Back to cited text no. 25
Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? Clin Cancer Res 1999;5:3645-52.  Back to cited text no. 26
Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine lewis lung carcinoma: The lack of beneficial effects by coating liposomes with poly (ethylene glycol). J Pharmacol Exp Ther 1997;280:1319-27.  Back to cited text no. 27
Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4:95-9.  Back to cited text no. 28
The use of liposomal doxorubicin (Myocet® ) in the management of metastatic breast cancer, October 2008. Available from: http://www.nyrdtc.nhs.uk/docs/eva/Myocet%202008%20FINAL%20(RDTC).pdf. [Last accessed on 2013 Feb 15].  Back to cited text no. 30
Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1:297-315.  Back to cited text no. 32
Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroR×2005;2:99-107.  Back to cited text no. 33
Shao K, Hou Q, Duan W, Go ML, Wong KP, Li QT. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas. J Control Release 2006;115:150-7.  Back to cited text no. 34
Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003;92:49-67.  Back to cited text no. 35
Itokazu M, Kumazawa S, Wada E, Wenyi Y. Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice. Cancer Lett 1996;107:11-8.  Back to cited text no. 36
Bromberg L, Alakhov V. Effects of polyether-modified poly (acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J Control Release 2003;88:11-22.  Back to cited text no. 37
Zocchi E, Tonetti M, Polvani C, Guida L, Benatti U, De Flora A. Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model. Proc Natl Acad Sci U S A 1989;86:2040-4.  Back to cited text no. 38
Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005;2:108-19.  Back to cited text no. 39
Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. J Control Release 2007;117:51-8.  Back to cited text no. 40
Wong HL, Rauth AM, Bendayan R, Wu XY. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm 2007;65:300-8.  Back to cited text no. 41
Dong Y, Feng SS. Poly (d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005;26:6068-76.  Back to cited text no. 42


  [Figure 1]

  [Table 1], [Table 2]

This article has been cited by
1 Drug-Loaded Mucoadhesive Patch with Active Delivery and Controlled Releasing Ability
Jihun Lee, Dong-in Kim, Seungmin Bang, Sukho Park
Advanced Intelligent Systems. 2022; : 2100203
[Pubmed] | [DOI]
2 Preclinical studies of the antitumor effect of curcumin-loaded polymeric nanocapsules: A systematic review and meta-analysis
Thayse V. de Oliveira, Renan Stein, Diego F. de Andrade, Ruy C. R. Beck
Phytotherapy Research. 2022;
[Pubmed] | [DOI]
3 Morin Inhibits Dox-Induced Vascular Inflammation By Regulating PTEN/AKT/NF-?B Pathway
Jing Yu, Hai-Liang Qi, Hong Zhang, Zi-Yu Zhao, Jing-Zhao, Zi-Yuan Nie
Inflammation. 2022;
[Pubmed] | [DOI]
4 Circ-LTBP1 is involved in doxorubicin-induced intracellular toxicity in cardiomyocytes via miR-107/ADCY1 signal
Chunxia Li, Lihui Zhang, Xingpeng Bu, Jinyu Wang, Li Li, Zhiming Yang
Molecular and Cellular Biochemistry. 2022;
[Pubmed] | [DOI]
5 Molecular relation between biological stress and carcinogenesis
Katarzyna Rakoczy, Wojciech Szlasa, Natalia Sauer, Jolanta Saczko, Julita Kulbacka
Molecular Biology Reports. 2022;
[Pubmed] | [DOI]
6 Hepatoprotective potential of the n-butanol extract of Moricandia arvensis from Algeria against doxorubicin induced toxicity in Wistar albino rats
Meriem Laraba, Sana Hazar Tachour, Hanene Belbache, Nassima Boubekri, Radja Djebbari, Fadila Benayache, Samir Benayache, Djamila Zama
Advances in Traditional Medicine. 2022;
[Pubmed] | [DOI]
7 Melatonin as an adjuvant treatment modality with doxorubicin
Parisa Maleki Dana, Fatemeh Sadoughi, Russel J. Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi
Biochimie. 2022;
[Pubmed] | [DOI]
8 Melatonin as an adjuvant treatment modality with doxorubicin
Parisa Maleki Dana, Fatemeh Sadoughi, Russel J.Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi
Biochimie. 2022;
[Pubmed] | [DOI]
9 Dosimetric assessment of antitumor treatment by enhanced bleomycin delivery via electroporation and sonoporation
Martynas Maciulevicius, Mindaugas Tamošiunas, Rytis Jurkonis, Saulius Šatkauskas
Bioelectrochemistry. 2022; 146: 108153
[Pubmed] | [DOI]
10 Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma
Muhammad Ismail, Wen Yang, Yanfei Li, Tianran Chai, Dongya Zhang, Qiuli Du, Pir Muhammad, Sumaira Hanif, Meng Zheng, Bingyang Shi
Biomaterials. 2022; : 121608
[Pubmed] | [DOI]
11 Heterocyclic Ring Expansion Yields Anthraquinone Derivatives Potent Against Multidrug Resistant Tumor Cells
Alexander S. Tikhomirov, Vladimir B. Tsvetkov, Yulia L. Volodina, Valeria A. Litvinova, Daria V. Andreeva, Lyubov G. Dezhenkova, Dmitry N. Kaluzhny, Ivan D. Treshalin, Alexander A. Shtil, Andrey E. Shchekotikhin
Bioorganic Chemistry. 2022; : 105925
[Pubmed] | [DOI]
12 Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib
Dou Yang, Feng Chen, Dan Gong, Lei Zeng, Deng Xiang, Yuanqiao He, Leifeng Chen, Jinlong Yan, Shouhua Zhang
Pediatric Surgery International. 2022;
[Pubmed] | [DOI]
13 Doxorubicin delivery systems with an acetylacetone-based block in cholesterol-terminated copolymers: diverse activity against estrogen-dependent and estrogen-independent breast cancer cells
Pawel Misiak, Katarzyna Niemirowicz-Laskowska, Iwona Misztalewska-Turkowicz, Karolina H. Markiewicz, Przemyslaw Wielgat, Halina Car, Agnieszka Z. Wilczewska
Chemistry and Physics of Lipids. 2022; : 105194
[Pubmed] | [DOI]
14 Characterization of Caerulomycin A as a dual-targeting anticancer agent
Lingying Tong, Weichao Sun, Shiyong Wu, Yong Han
European Journal of Pharmacology. 2022; 922: 174914
[Pubmed] | [DOI]
15 Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx®: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer
S.S. Prakash, Rajnish Vasant Nagarkar, Krishna Chaitanya Puligundla, K.N. Lokesh, Rakesh Reddy Boya, Ankit Baldevbhai Patel, Lovenish Goyal, Aniket Thoke, Jigar Gordhanbhai Patel, Ajay Omprakash Mehta, Ghanshyam Nanubhai Patel, Mujtaba A. Khan, Imran Ahmad
European Journal of Pharmaceutical Sciences. 2022; : 106248
[Pubmed] | [DOI]
16 Oleanolic Acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma
Soniya Kumbham, Milan Paul, Asif Itoo, Balaram Ghosh, Swati Biswas
International Journal of Pharmaceutics. 2022; : 121479
[Pubmed] | [DOI]
17 Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies
Zahra Jamshidi, Taraneh Sadat Zavvar, Mohammad Ramezani, Mona Alibolandi, Farzin Hadizadeh, Khalil Abnous, Seyed Mohammad Taghdisi
International Journal of Pharmaceutics. 2022; : 121892
[Pubmed] | [DOI]
18 Design and optimization of PEGylated silver nanoparticles for efficient delivery of doxorubicin to cancer cells
Ahmed Abdelfattah, Ahmed E. Aboutaleb, Abu-Baker M. Abdel-Aal, Ahmed A.H. Abdellatif, Hesham M. Tawfeek, Sayed I. Abdel-Rahman
Journal of Drug Delivery Science and Technology. 2022; : 103347
[Pubmed] | [DOI]
19 Free- and liposomal- doxorubicin delivery via microbubble inertial cavitation
Martynas Maciulevicius, Mindaugas Tamošiunas, Diana Navickaite, Saulius Šatkauskas, Mindaugas S. Venslauskas
Journal of Drug Delivery Science and Technology. 2022; : 103386
[Pubmed] | [DOI]
20 Hydrazone modified nanoscale metal-organic frameworks as pH responsive nanoplatforms for cancer therapy
Datian Fu, Yan Wang, Jin Xu, Haimei Wu
Journal of Solid State Chemistry. 2022; 310: 123029
[Pubmed] | [DOI]
21 Protective effects of berberine on various kidney diseases: Emphasis on the promising effects and the underlined molecular mechanisms
Emad H.M. Hassanein, Islam M. Ibrahim, Esraa K. Abd-alhameed, Nesma M. Mohamed, Samir A. Ross
Life Sciences. 2022; : 120697
[Pubmed] | [DOI]
22 Doxorubicin-induced senescence in normal fibroblasts promotes in vitro tumour cell growth and invasiveness: the role of Quercetin in modulating these processes
Elisa Bientinesi, Matteo Lulli, Matteo Becatti, Sara Ristori, Francesca Margheri, Daniela Monti
Mechanisms of Ageing and Development. 2022; : 111689
[Pubmed] | [DOI]
23 Apocynum venetum leaf extract alleviated doxorubicin-induced cardiotoxicity through the AKT/Bcl-2 signaling pathway
Yang Zhang, Shan Liu, Jiu-Long Ma, Chen Chen, Peng Huang, Jia-Hua Ji, Di Wu, Li-Qun Ren
Phytomedicine. 2022; 94: 153815
[Pubmed] | [DOI]
24 Greenness estimation of chromatographic assay for the determination of anthracycline-based antitumor drug in bacterial ghost matrix of Salmonella typhimurium
Nazrul Haq, Fars K. Alanazi, Mounir M. Salem-Bekhit, Sameh Rabea, Prawez Alam, Ibrahim A. Alsarra, Faiyaz Shakeel
Sustainable Chemistry and Pharmacy. 2022; 26: 100642
[Pubmed] | [DOI]
25 Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders
Margarita E. Neganova, Yulia R. Aleksandrova, Olga A. Sukocheva, Sergey G. Klochkov
Seminars in Cancer Biology. 2022;
[Pubmed] | [DOI]
26 Engineering Chemotherapeutic-Augmented Calcium Phosphate Nanoparticles for Treatment of Intraperitoneal Disseminated Ovarian Cancer
Miaojuan Qiu, Junzong Chen, Xiuyu Huang, Binbin Li, Shiqiang Zhang, Peng Liu, Qiang Wang, Zhi Rong Qian, Yihang Pan, Yu Chen, Jing Zhao
ACS Applied Materials & Interfaces. 2022;
[Pubmed] | [DOI]
27 NUIG4: A biocompatible pcu metal–organic framework with an exceptional doxorubicin encapsulation capacity
Ahmed Ahmed, Constantinos G. Efthymiou, Rana Sanii, Ewa Patyk-Kazmierczak, Amir M. Alsharabasy, Meghan Winterlich, Naveen Kumar, Debobroto Sensharma, Wenming Tong, Sarah Guerin, Pau Farras, Sarah Hudson, Damien Thompson, Michael J. Zaworotko, Anastasios J. Tasiopoulos, Constantina Papatriantafyllopoulou
Journal of Materials Chemistry B. 2022;
[Pubmed] | [DOI]
28 Current Insights into Cellular Senescence and Myotoxicity Induced by Doxorubicin: The Role of Exercise and Growth Factors
Charalampos Andreou, Antonios Matsakas
International Journal of Sports Medicine. 2022;
[Pubmed] | [DOI]
29 Bixin Prevents Colorectal Cancer Development through AMPK-Activated Endoplasmic Reticulum Stress
Yunfeng Qiu, Changfeng Li, Bin Zhang, Yue Gu
BioMed Research International. 2022; 2022: 1
[Pubmed] | [DOI]
30 Progress in drug-delivery systems in cardiovascular applications: stents, balloons and nanoencapsulation
Jaryl Chen Koon Ng, Daniel Wee Yee Toong, Valerie Ow, Su Yin Chaw, Hanwei Toh, Philip En Hou Wong, Subbu Venkatraman, Tze Tec Chong, Lay Poh Tan, Ying Ying Huang, Hui Ying Ang
Nanomedicine. 2022;
[Pubmed] | [DOI]
31 A Review of Pharmacology, Toxicity and Pharmacokinetics of 2,3,5,4'-Tetrahydroxystilbene-2-O-ß-D-Glucoside
Cheng Wang, Shu Dai, Lihong Gong, Ke Fu, Cheng Ma, Yanfang Liu, Honglin Zhou, Yunxia Li
Frontiers in Pharmacology. 2022; 12
[Pubmed] | [DOI]
32 Thioredoxin-1 Activation by Pterostilbene Protects Against Doxorubicin-Induced Hepatotoxicity via Inhibiting the NLRP3 Inflammasome
Shiqing Tan, Jie Bai, Mingxi Xu, Longying Zhang, Ying Wang
Frontiers in Pharmacology. 2022; 13
[Pubmed] | [DOI]
33 Cariporide Attenuates Doxorubicin-Induced Cardiotoxicity in Rats by Inhibiting Oxidative Stress, Inflammation and Apoptosis Partly Through Regulation of Akt/GSK-3ß and Sirt1 Signaling Pathway
Wenli Liao, Zhiwei Rao, Lingling Wu, Yong Chen, Cairong Li
Frontiers in Pharmacology. 2022; 13
[Pubmed] | [DOI]
34 Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance
Ying Liu, Xiang Ao, Yu Wang, Xiaoge Li, Jianxun Wang
Frontiers in Oncology. 2022; 12
[Pubmed] | [DOI]
35 Smart Lipid–Polysaccharide Nanoparticles for Targeted Delivery of Doxorubicin to Breast Cancer Cells
Manuela Curcio, Matteo Brindisi, Giuseppe Cirillo, Luca Frattaruolo, Antonella Leggio, Vittoria Rago, Fiore Pasquale Nicoletta, Anna Rita Cappello, Francesca Iemma
International Journal of Molecular Sciences. 2022; 23(4): 2386
[Pubmed] | [DOI]
36 Nanoliposomes in Cancer Therapy: Marketed Products and Current Clinical Trials
Raquel Taléns-Visconti, Octavio Díez-Sales, Jesus Vicente de Julián-Ortiz, Amparo Nácher
International Journal of Molecular Sciences. 2022; 23(8): 4249
[Pubmed] | [DOI]
37 Impact of Doxorubicin on Cell-Substrate Topology
Andreas Krecsir, Verena Richter, Michael Wagner, Herbert Schneckenburger
International Journal of Molecular Sciences. 2022; 23(11): 6277
[Pubmed] | [DOI]
38 Design and Synthesis of Menthol and Thymol Derived Ciprofloxacin: Influence of Structural Modifications on the Antibacterial Activity and Anticancer Properties
Tomasz Szostek, Daniel Szulczyk, Jolanta Szymanska-Majchrzak, Michal Kolinski, Sebastian Kmiecik, Dagmara Otto-Slusarczyk, Aleksandra Zawodnik, Eliza Rajkowska, Kinga Chaniewicz, Marta Struga, Piotr Roszkowski
International Journal of Molecular Sciences. 2022; 23(12): 6600
[Pubmed] | [DOI]
39 The Mechanism of Dynamic Interaction between Doxorubicin and Calf Thymus DNA at the Single-Molecule Level Based on Confocal Raman Spectroscopy
Ruihong Zhang, Jie Zhu, Dan Sun, Jie Li, Lina Yao, Shuangshuang Meng, Yan Li, Yang Dang, Kaige Wang
Micromachines. 2022; 13(6): 940
[Pubmed] | [DOI]
40 Targeted Drug Delivery Biopolymers Effectively Inhibit Breast Tumor Growth and Prevent Doxorubicin-Induced Cardiotoxicity
Sonja Dragojevic, Jung Su Ryu, Michael E. Hall, Drazen Raucher
Molecules. 2022; 27(11): 3371
[Pubmed] | [DOI]
41 Synthesis of a new water-soluble hexacarboxylated tribenzotriquinacene derivative and its competitive host–guest interaction for drug delivery
Man-Ping Li, Nan Yang, Wen-Rong Xu
Beilstein Journal of Organic Chemistry. 2022; 18: 539
[Pubmed] | [DOI]
42 Dual-Targeted Hyaluronic Acid/Albumin Micelle-Like Nanoparticles for the Vectorization of Doxorubicin
Manuela Curcio, Luis Diaz-Gomez, Giuseppe Cirillo, Fiore Pasquale Nicoletta, Antonella Leggio, Francesca Iemma
Pharmaceutics. 2021; 13(3): 304
[Pubmed] | [DOI]
43 Os Efeitos da Doxorrubicina na Biossíntese e no Metabolismo do Heme em Cardiomiócitos
Zuoyan Wang, Junyi Gao, Haobo Teng, Jianjun Peng
Arquivos Brasileiros de Cardiologia. 2021; 116(2): 315
[Pubmed] | [DOI]
44 Role of Creatine in the Heart: Health and Disease
Maurizio Balestrino
Nutrients. 2021; 13(4): 1215
[Pubmed] | [DOI]
45 The Effects of Bergamot Polyphenolic Fraction, Cynara cardunculus, and Olea europea L. Extract on Doxorubicin-Induced Cardiotoxicity
Jessica Maiuolo, Irene Bava, Cristina Carresi, Micaela Gliozzi, Vincenzo Musolino, Federica Scarano, Saverio Nucera, Miriam Scicchitano, Francesca Bosco, Stefano Ruga, Maria Caterina Zito, Francesca Oppedisano, Roberta Macri, Annamaria Tavernese, Rocco Mollace, Vincenzo Mollace
Nutrients. 2021; 13(7): 2158
[Pubmed] | [DOI]
46 Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance
Nirmala Tilija Pun, Chul-Ho Jeong
Pharmaceuticals. 2021; 14(5): 470
[Pubmed] | [DOI]
47 Thymoquinone and its nanoformulation attenuate colorectal and breast cancers and alleviate doxorubicin-induced cardiotoxicity
Ali H El-Far, Taher A Salaheldin, Kavitha Godugu, Noureldien HE Darwish, Shaker A Mousa
Nanomedicine. 2021; 16(17): 1457
[Pubmed] | [DOI]
48 Hyperthermia Enhances Doxorubicin Therapeutic Efficacy against A375 and MNT-1 Melanoma Cells
Diana Salvador, Verónica Bastos, Helena Oliveira
International Journal of Molecular Sciences. 2021; 23(1): 35
[Pubmed] | [DOI]
49 Cold Atmospheric Plasma: A New Strategy Based Primarily on Oxidative Stress for Osteosarcoma Therapy
Miguel Mateu-Sanz, Juan Tornín, Maria-Pau Ginebra, Cristina Canal
Journal of Clinical Medicine. 2021; 10(4): 893
[Pubmed] | [DOI]
50 A Review on Drug Delivery System for Tumor Therapy
Guoxiang Liu, Lina Yang, Guang Chen, Fenghua Xu, Fanghao Yang, Huaxin Yu, Lingne Li, Xiaolei Dong, Jingjing Han, Can Cao, Jingyu Qi, Junzhe Su, Xiaohui Xu, Xiaoxia Li, Bing Li
Frontiers in Pharmacology. 2021; 12
[Pubmed] | [DOI]
51 Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer
Rama Prajapati, Eduardo Garcia-Garrido, Álvaro Somoza
Cancers. 2021; 13(12): 3011
[Pubmed] | [DOI]
52 Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study
Hsin-Ying Huang, Chun-Ju Chiang, Yun-Yuan Chen, San-Lin You, Heng-Cheng Hsu, Chao-Hsiun Tang, Wen-Fang Cheng
International Journal of Environmental Research and Public Health. 2021; 18(12): 6629
[Pubmed] | [DOI]
53 Synergistic Antitumor Activity of Gramicidin/Lipophilic Bismuth Nanoparticles (BisBAL NPs) on Human Cervical Tumor Cells
Claudio Cabral-Romero, Claudia María García-Cuellar, Rene Hernandez-Delgadillo, Yesennia Sánchez-Pérez, Irene Meester, Juan Manuel Solís-Soto, Nayely Pineda-Aguilar, Shankararaman Chellam
Frontiers in Nanotechnology. 2021; 3
[Pubmed] | [DOI]
54 A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer
Maolin Wang, Xing-sheng Shu, Meiqi Li, Yilin Zhang, Youli Yao, Xiaoyan Huang, Jianna Li, Pengfei Wei, Zhendan He, Jun Lu, Ying Ying
Frontiers in Oncology. 2021; 11
[Pubmed] | [DOI]
55 Protective effects and mechanism of coenzyme Q10 and vitamin C on doxorubicin-induced gastric mucosal injury and effects of intestinal flora
Xiaomeng Zhao, Xueke Feng, Nan Ye, Panpan Wei, Zhanwei Zhang, Wenyu Lu
The Korean Journal of Physiology & Pharmacology. 2021; 25(4): 261
[Pubmed] | [DOI]
56 Regulatory role of the transforming growth factor-ß signaling pathway in the drug resistance of gastrointestinal cancers
Xiaoqun Lv, Guoxiong Xu
World Journal of Gastrointestinal Oncology. 2021; 13(11): 1648
[Pubmed] | [DOI]
57 Evaluation of Anti-Cancer Effects of Caspian Cobra (Naja naja oxiana) Snake Venom in Comparison with Doxorubicin in HeLa Cancer Cell Line and Normal HFF Fibroblast
Fatemeh Javani Jouni, Jaber Zafari, Elaheh Shams, Parviz Abdolmaleki, Ali asghar Rastegari
journal of ilam university of medical sciences. 2021; 29(6): 20
[Pubmed] | [DOI]
58 Breast cancer: Muscarinic receptors as new targets for tumor therapy
Alejandro Español, Agustina Salem, Yamila Sanchez, María Elena Sales
World Journal of Clinical Oncology. 2021; 12(6): 404
[Pubmed] | [DOI]
59 Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma
Ekaterina Proskuriakova, Keji Jada, Sandrine Kakieu Djossi, Anwar Khedr, Bandana Neupane, Jihan A Mostafa
Cureus. 2021;
[Pubmed] | [DOI]
60 Cancer—A Major Cardiac Comorbidity With Implications on Cardiovascular Metabolism
Daniel Finke, Markus B. Heckmann, Norbert Frey, Lorenz H. Lehmann
Frontiers in Physiology. 2021; 12
[Pubmed] | [DOI]
61 Diosmin Alleviates Doxorubicin-Induced Liver Injury via Modulation of Oxidative Stress-Mediated Hepatic Inflammation and Apoptosis via NfkB and MAPK Pathway: A Preclinical Study
Abdullah F. AlAsmari, Metab Alharbi, Faleh Alqahtani, Fawaz Alasmari, Mohammed AlSwayyed, Sami I. Alzarea, Ibrahim A. Al-Alallah, Adel Alghamdi, Hassan M. Hakami, Meshal K. Alyousef, Youssef Sari, Nemat Ali
Antioxidants. 2021; 10(12): 1998
[Pubmed] | [DOI]
62 Anthraquinones as Inhibitors of SOS RAS-GEF Activity
Alberto Fernández-Medarde, Rocío Fuentes-Mateos, Rósula García-Navas, Andrea Olarte-San Juan, José María Sánchez-López, Antonio Fernández-Medarde, Eugenio Santos
Biomolecules. 2021; 11(8): 1128
[Pubmed] | [DOI]
63 Nanonutraceuticals: Anti-Cancer Activity and Improved Safety of Chemotherapy by Costunolide and Its Nanoformulation against Colon and Breast Cancer
Ali H. El-Far, Kavitha Godugu, Taher A. Salaheldin, Noureldien H. E. Darwish, Amna A. Saddiq, Shaker A. Mousa
Biomedicines. 2021; 9(8): 990
[Pubmed] | [DOI]
64 Surface PEGylated Cancer Cell Membrane-Coated Nanoparticles for Codelivery of Curcumin and Doxorubicin for the Treatment of Multidrug Resistant Esophageal Carcinoma
Yi Gao, Yue Zhu, Xiaopeng Xu, Fangjun Wang, Weidong Shen, Xia Leng, Jiyi Zhao, Bingtuan Liu, Yangyun Wang, Pengfei Liu
Frontiers in Cell and Developmental Biology. 2021; 9
[Pubmed] | [DOI]
65 Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma
Yongqiang Zhang, Yuqin Tang, Chengbin Guo, Gen Li
Aging. 2021; 13(9): 12865
[Pubmed] | [DOI]
66 Roflumilast Attenuates Doxorubicin-Induced Cardiotoxicity by Targeting Inflammation and Cellular Senescence in Cardiomyocytes Mediated by SIRT1
Sheng Zhang, Peng Wu, Jiabao Liu, Yingqiang Du, Zhijian Yang
Drug Design, Development and Therapy. 2021; Volume 15: 87
[Pubmed] | [DOI]
67 ß-Elemene Enhances the Sensitivity of Osteosarcoma Cells to Doxorubicin via Downregulation of Peroxiredoxin-1
Shaochun Zhang, Weichun Guo
OncoTargets and Therapy. 2021; Volume 14: 3599
[Pubmed] | [DOI]
68 Isoliquiritigenin ameliorates doxorubicin-induced acute pancreatitis by inhibiting ROS production via modulation of Nrf2/HO-1 oxidative stress pathway
Chen-Chen Yuan, Qing-Tian Zhu, Qin-Hao Shen, Xing-Meng Xu, Yao Xu, Qi Yang, Bai-Qiang Li, Guo-Tao Lu, Wei-Qin Li
World Chinese Journal of Digestology. 2021; 29(6): 282
[Pubmed] | [DOI]
69 Immunomodulatory effects of bee pollen on doxorubicin-induced bone marrow/spleen immunosuppression in rat
Fayez Shaldoum, Attalla F. El-kott, Marwa Mohamed Ahmed Ouda, Eman M. Abd-Ella
Journal of Food Biochemistry. 2021; 45(6)
[Pubmed] | [DOI]
70 Reduction of doxorubicin-induced cytotoxicity and mitochondrial damage by betanin in rat isolated cardiomyocytes and mitochondria
AA Hafez, Z Jamali, S Samiei, S Khezri, A Salimi
Human & Experimental Toxicology. 2021; 40(12): 2123
[Pubmed] | [DOI]
71 Thymoquinone and Costunolide Induce Apoptosis of Both Proliferative and Doxorubicin-Induced-Senescent Colon and Breast Cancer Cells
Ali H El-Far, Kavitha Godugu, Ahmed E. Noreldin, Amna A. Saddiq, Omar A. Almaghrabi, Soad K. Al Jaouni, Shaker A. Mousa
Integrative Cancer Therapies. 2021; 20: 1534735421
[Pubmed] | [DOI]
72 Platelet-rich plasma inhibits Adriamycin-induced inflammation via blocking the NF-?B pathway in articular chondrocytes
Haijun Zhao, Weijie Zhu, Wude Mao, Chengkai Shen
Molecular Medicine. 2021; 27(1)
[Pubmed] | [DOI]
73 A novel formulation of theranostic nanomedicine for targeting drug delivery to gastrointestinal tract cancer
Madeeha Shahzad Lodhi, Muhammad Tahir Khan, Saira Aftab, Zahoor Qadir Samra, Heng Wang, Dong Qing Wei
Cancer Nanotechnology. 2021; 12(1)
[Pubmed] | [DOI]
74 Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer
Khine Kyaw Oo, Thanpawee Kamolhan, Anish Soni, Suyanee Thongchot, Chalermchai Mitrpant, Pornchai O-charoenrat, Chanitra Thuwajit, Peti Thuwajit
BMC Cancer. 2021; 21(1)
[Pubmed] | [DOI]
75 Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines
Michela Levi, Roberta Salaroli, Federico Parenti, Raffaella De Maria, Augusta Zannoni, Chiara Bernardini, Cecilia Gola, Antonio Brocco, Asia Marangio, Cinzia Benazzi, Luisa Vera Muscatello, Barbara Brunetti, Monica Forni, Giuseppe Sarli
BMC Veterinary Research. 2021; 17(1)
[Pubmed] | [DOI]
76 Hsa_circ_0004674 promotes osteosarcoma doxorubicin resistance by regulating the miR-342-3p/FBN1 axis
Yumei Bai, Yanghua Li, Juan Bai, Yumei Zhang
Journal of Orthopaedic Surgery and Research. 2021; 16(1)
[Pubmed] | [DOI]
77 miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer
Hui Zhang, Xiao-Dong Zheng, Xiao-Hua Zeng, Li Li, Qi Zhou
YAKUGAKU ZASSHI. 2021; 141(3): 415
[Pubmed] | [DOI]
78 Evaluation of Cytotoxicity Induced by the Anti-Cancerous Drugs Doxorubicin and Erlotinib in Allium cepa Assay for Eco-Safety Monitoring
Debadrito Das, Prashanta Kumar Mitra, Sudha Gupta
CYTOLOGIA. 2021; 86(3): 195
[Pubmed] | [DOI]
79 Circ-SKA3 Enhances Doxorubicin Toxicity in AC16 Cells Through miR-1303/TLR4 Axis
Bin Li, Xinyong Cai, Yunxia Wang, Hongmin Zhu, Ping Zhang, Panpan Jiang, Xu Yang, Jianhua Sun, Lang Hong, Liang Shao
International Heart Journal. 2021; 62(5): 1112
[Pubmed] | [DOI]
80 Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition
Fu-Yi Cai, Xue-Min Yao, Ming Jing, Liang Kong, Jing-Jing Liu, Min Fu, Xin-Ze Liu, Lu Zhang, Si-Yu He, Xue-Tao Li, Rui-Jun Ju
Journal of Liposome Research. 2021; 31(2): 113
[Pubmed] | [DOI]
81 Loading of doxorubicin on poly(methyl methacrylate-co-methacrylic acid) nanoparticles and release study
Roberto López-Muñoz, María Esther Treviño, Fabiola Castellanos, Graciela Morales, Oliverio Rodríguez-Fernández, Santiago Saavedra, Angel Licea-Claverie, Hened Saade, Francisco Javier Enríquez-Medrano, Raúl Guillermo López
Journal of Biomaterials Science, Polymer Edition. 2021; 32(9): 1107
[Pubmed] | [DOI]
82 Role of miRNAs in regulating responses to radiotherapy in human breast cancer
Zhi Xiong Chong, Swee Keong Yeap, Wan Yong Ho
International Journal of Radiation Biology. 2021; 97(3): 289
[Pubmed] | [DOI]
83 Toxic effects and molecular mechanism of doxorubicin on different organs – an update
Kaviyarasi Renu, Lakshmi Prasanna Pureti, Balachandar Vellingiri, Abilash Valsala Gopalakrishnan
Toxin Reviews. 2021; : 1
[Pubmed] | [DOI]
84 Differential Effects of p-Coumaric Acid in relieving Doxorubicin induced Cardiotoxicity in Solid Tumour Bearing and Non-tumor Bearing Mice
Sunitha Mary Chacko, R DhanyaKrishnan, Kottayath Govindan Nevin
Journal of Biologically Active Products from Nature. 2021; 11(2): 138
[Pubmed] | [DOI]
85 Dual covalent functionalization of single-walled carbon nanotubes for effective targeted cancer therapy
Mohyeddin Assali, Naim Kittana, Safa’ Dayyeh, Noureddine Khiar
Nanotechnology. 2021; 32(20): 205101
[Pubmed] | [DOI]
86 Engineering the early bone metastatic niche through human vascularized immuno bone minitissues
Maria Vittoria Colombo, Simone Bersini, Chiara Arrigoni, Mara Gilardi, Veronica Sansoni, Enrico Ragni, Gabriele Candiani, Giovanni Lombardi, Matteo Moretti
Biofabrication. 2021; 13(3): 035036
[Pubmed] | [DOI]
87 Ozone Attenuated H9c2 Cell Injury Induced by Doxorubicin
Lingshan Xu, Chenhao Wang, Zhiqing Zou, Zhouquan Wu
Journal of Cardiovascular Pharmacology. 2021; 78(1): e86
[Pubmed] | [DOI]
88 The application of aluminium phthalocyanine AlPs-4-mediated photodynamic therapy against human soft tissue sarcoma (RMS) cell line
Muhammad Zakir, Ahmat Khurshid, Muhammad Iqbal Khan, Asma Khattak, Murad Ali Khan
Journal of Porphyrins and Phthalocyanines. 2021; 25(02): 102
[Pubmed] | [DOI]
89 Polyethylenimine–Bisphosphonate–Cyclodextrin Ternary Conjugates: Supramolecular Systems for the Delivery of Antineoplastic Drugs
Simona Plesselova, Pablo Garcia-Cerezo, Victor Blanco, Francisco J. Reche-Perez, Fernando Hernandez-Mateo, Francisco Santoyo-Gonzalez, María Dolores Giron-Gonzalez, Rafael Salto-Gonzalez
Journal of Medicinal Chemistry. 2021; 64(16): 12245
[Pubmed] | [DOI]
90 Thymic function affects breast cancer development and metastasis by regulating expression of thymus secretions PTMa and Tß15b1
Dongling Shi, Yanmei Shui, Xie Xu, Kai He, Fengqing Yang, Jianli Gao
Translational Oncology. 2021; 14(1): 100980
[Pubmed] | [DOI]
91 Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?
Mojtaba Mollaei, Zuhair Mohammad Hassan, Fatemeh Khorshidi, Ladan Langroudi
Translational Oncology. 2021; 14(5): 101056
[Pubmed] | [DOI]
92 AIE-Based Fluorescent Triblock Copolymer Micelles for Simultaneous Drug Delivery and Intracellular Imaging
Bhagyashree Kulkarni, Somayah Qutub, Viko Ladelta, Niveen M. Khashab, Nikos Hadjichristidis
Biomacromolecules. 2021;
[Pubmed] | [DOI]
93 Miniatured Fluidics-Mediated Modular Self-Assembly of Anticancer Drug–Amino Acid Composite Microbowls for Combined Chemo-Photodynamic Therapy in Glioma
Sonika Chibh, Vibhav Katoch, Manish Singh, Bhanu Prakash, Jiban Jyoti Panda
ACS Biomaterials Science & Engineering. 2021;
[Pubmed] | [DOI]
94 ?-Ray-Triggered Drug Release of Reactive Oxygen Species-Sensitive Nanomedicine for Enhanced Concurrent Chemoradiation Therapy
Ying Yu, Zujian Feng, Jinjian Liu, Xiaoxue Hou, Xiaoqian Zhou, Jie Gao, Wei Wang, Yumin Zhang, Guoliang Li, Jianfeng Liu
ACS Omega. 2021; 6(30): 19445
[Pubmed] | [DOI]
95 Two-dimensional materials in biomedical, biosensing and sensing applications
Nasuha Rohaizad, Carmen C. Mayorga-Martinez, Michaela Fojtu, Naziah M. Latiff, Martin Pumera
Chemical Society Reviews. 2021; 50(1): 619
[Pubmed] | [DOI]
96 Aptamers: an emerging navigation tool of therapeutic agents for targeted cancer therapy
Chang Yang, Yu Jiang, Sai Heng Hao, Xing Yi Yan, De Fei Hong, Hua Naranmandura
Journal of Materials Chemistry B. 2021;
[Pubmed] | [DOI]
97 Irisin ameliorates doxorubicin-induced cardiac perivascular fibrosis through inhibiting endothelial-to-mesenchymal transition by regulating ROS accumulation and autophagy disorder in endothelial cells
Jian-an Pan, Hui Zhang, Hao Lin, Lin Gao, Hui-li Zhang, Jun-feng Zhang, Chang-qian Wang, Jun Gu
Redox Biology. 2021; 46: 102120
[Pubmed] | [DOI]
98 Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma
Maurizio Viale, Vittorio Bertone, Irena Maric, Michele Cilli, Laura Emionite, Vittorio Bocchini, Mirco Ponzoni, Vincenzo Fontana, Fabrizio De Luca, Mattia Rocco
Pharmacological Research. 2021; 163: 105294
[Pubmed] | [DOI]
99 Evidences for the mechanism of Shenmai injection antagonizing doxorubicin-induced cardiotoxicity
You-Ping Wu, Sheng Zhang, Yan-Fei Xin, Li-Qiang Gu, Xiao-Zhen Xu, Cheng-Da Zhang, Zhen-Qiang You
Phytomedicine. 2021; 88: 153597
[Pubmed] | [DOI]
100 Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
Hemat Afifi Sherif, Ahmed Magdy, Heba Anees Elshesheni, Sherein Mahmoud Ramadan, Reham A. Rashed
Leukemia Research Reports. 2021; 16: 100272
[Pubmed] | [DOI]
101 Tumor targeting antibody-conjugated nanocarrier with pH/thermo dual-responsive macromolecular film layer for enhanced cancer chemotherapy
Jiafeng Zhuang, Lina Zhou, Wen Tang, Tonghao Ma, Hui Li, Xiaoli Wang, Chao Chen, Ping Wang
Materials Science and Engineering: C. 2021; 118: 111361
[Pubmed] | [DOI]
102 Doxorubicin nanoformulations on therapy against cancer: An overview from the last 10?years
Natália A. D'Angelo, Mariana A. Noronha, Mayra C.C. Câmara, Isabelle S. Kurnik, Chuying Feng, Victor H.S. Araujo, João H.P.M. Santos, Valker Feitosa, João V.D. Molino, Carlota O. Rangel-Yagui, Marlus Chorilli, Emmanuel Ho, André M. Lopes
Materials Science and Engineering: C. 2021; : 112623
[Pubmed] | [DOI]
103 Cellulose acetate encapsulated upconversion nanoparticles – A novel theranostic platform
Seda Demirel Topel, Sevgi Balcioglu, Burhan Ates, Meltem Asilturk, Önder Topel, Marica B. Ericson
Materials Today Communications. 2021; 26: 101829
[Pubmed] | [DOI]
104 Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy
Quan Liu, Yanhong Duo, Jianye Fu, Meng Qiu, Zhe Sun, Dickson Adah, Jianlong Kang, Zhongjian Xie, Taojian Fan, Shiyun Bao, Han Zhang, Li-Ping Liu, Yihai Cao
Nano Today. 2021; 36: 101023
[Pubmed] | [DOI]
105 Synergetic effect of adsorption-photocatalysis by GO-CeO2nanocomposites for photodegradation of doxorubicin
M. Ali Abbasi, Khaled M. Amin, Mubarak Ali, Zulqurnain Ali, Muhammad Atif, Wolfgang Ensinger, Waqas Khalid
Journal of Environmental Chemical Engineering. 2021; : 107078
[Pubmed] | [DOI]
106 Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization
Vivek Makwana, Jasmine Karanjia, Thomas Haselhorst, Shailendra Anoopkumar-Dukie, Santosh Rudrawar
International Journal of Pharmaceutics. 2021; 593: 120117
[Pubmed] | [DOI]
107 Construction and antitumor properties of a targeted nano-drug carrier system responsive to the tumor microenvironment
Wenzhao Han, Junfeng Ke, Feng Guo, Fanwei Meng, Hui Li, Liping Wang
International Journal of Pharmaceutics. 2021; 608: 121066
[Pubmed] | [DOI]
108 Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma
Naghmeh Shahraki, Amin Mehrabian, Shahrazad Amiri-Darban, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari
Colloids and Surfaces B: Biointerfaces. 2021; 200: 111589
[Pubmed] | [DOI]
109 Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma
Weijie Qiang, Yifei Dai, Xiaoyan Xing, Xiaobo Sun
Computational and Structural Biotechnology Journal. 2021; 19: 1263
[Pubmed] | [DOI]
110 Sensitive analysis of doxorubicin and curcumin by micellar electromagnetic chromatography with a double wavelength excitation source
Xiao Yu, Wanxiang Yu, Xiufen Han, Zuanguang Chen, Shumei Wang, Haiyun Zhai
Analytical and Bioanalytical Chemistry. 2021; 413(2): 469
[Pubmed] | [DOI]
111 Folic acid-appended galactoxyloglucan-capped iron oxide nanoparticles as a biocompatible nanotheranostic agent for tumor-targeted delivery of doxorubicin
B.S. Unnikrishnan, Anitha Sen, G.U. Preethi, Manu M. Joseph, S. Maya, R. Shiji, K.S. Anusree, T.T. Sreelekha
International Journal of Biological Macromolecules. 2021; 168: 130
[Pubmed] | [DOI]
112 Doxorubicin delivery by magnetic nanotheranostics enhances the cell death in chemoresistant colorectal cancer-derived cells
María Julia Martín, Pamela Azcona, Verónica Lassalle, Claudia Gentili
European Journal of Pharmaceutical Sciences. 2021; 158: 105681
[Pubmed] | [DOI]
113 Folic acid-doxorubicin polymeric nanocapsules: A promising formulation for the treatment of triple-negative breast cancer
Rodrigo Cé, Gabriela Klein Couto, Barbara Zoche Pacheco, Danieli Rosane Dallemole, Júlia Damé Paschoal, Bruna Silveira Pacheco, Silvia Stanisçuaski Guterres, Fabiana Seixas, Tiago Collares, Adriana Raffin Pohlmann
European Journal of Pharmaceutical Sciences. 2021; 165: 105943
[Pubmed] | [DOI]
114 Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production
Cheng Wu, Jiayi Luo, Yuanxin Liu, Jiannan Fan, Xianwen Shang, Riguang Liu, Chuan Ye, Jihong Yang, Hong Cao
European Journal of Pharmaceutical Sciences. 2021; 167: 106013
[Pubmed] | [DOI]
115 Effective drug delivery system based on hydrophobin and halloysite clay nanotubes for sustained release of doxorubicin
Bo Wang, Zhiqiang Han, Bo Song, Long Yu, Zhongqiang Ma, Haijin Xu, Mingqiang Qiao
Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2021; 628: 127351
[Pubmed] | [DOI]
116 Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy
Marina Curra, Amanda F. Gabriel, Maria Beatriz C. Ferreira, Marco Antonio T. Martins, André T. Brunetto, Lauro J. Gregianin, Manoela Domingues Martins
Supportive Care in Cancer. 2021; 29(11): 6243
[Pubmed] | [DOI]
117 The role of miRNAs in colorectal cancer progression and chemoradiotherapy
Ning Zhang, Xianyu Hu, Yinan Du, Juan Du
Biomedicine & Pharmacotherapy. 2021; 134: 111099
[Pubmed] | [DOI]
118 The nephroprotective effects and mechanisms of rehmapicrogenin include ROS inhibition via an oestrogen-like pathway both in vivo and in vitro
Mengmeng Wang, Yingying Ke, Yage Li, Zengfu Shan, Wangyang Mi, Yangang Cao, Weisheng Feng, Xiaoke Zheng
Biomedicine & Pharmacotherapy. 2021; 138: 111305
[Pubmed] | [DOI]
119 DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy
Larissa Costa de Almeida, Felipe Antunes Calil, João Agostinho Machado-Neto, Leticia Veras Costa-Lotufo
Cancer Genetics. 2021; 252-253: 6
[Pubmed] | [DOI]
120 Intracellular RNA and nuclear DNA-dual-targeted tumor therapy via upconversion nanoplatforms with UCL/MR dual-mode bioimaging
Bo Teng, Binbin Ding, Shuai Shao, Zhanfeng Wang, Weifang Tong, Sanchun Wang, Ziyong Cheng, Jun Lin, Ping'an Ma
Chemical Engineering Journal. 2021; 405: 126606
[Pubmed] | [DOI]
121 A bioimaging system combining human cultured reporter cells and planar chromatography to identify novel bioactive molecules
Ines Klingelhöfer, Long Pham Ngoc, Bart van der Burg, Gertrud E. Morlock
Analytica Chimica Acta. 2021; 1183: 338956
[Pubmed] | [DOI]
122 Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma
Yang Liu, Deepak Bushan Raina, Sujeesh Sebastian, Harshitha Nagesh, Hanna Isaksson, Jacob Engellau, Lars Lidgren, Magnus Tägil
Acta Biomaterialia. 2021; 131: 555
[Pubmed] | [DOI]
123 Optical properties of natural small molecules and their applications in imaging and nanomedicine
Hao Yuan, Ao Jiang, Hongbao Fang, Yuncong Chen, Zijian Guo
Advanced Drug Delivery Reviews. 2021; : 113917
[Pubmed] | [DOI]
124 Application of new multicomponent nanosystems for overcoming doxorubicin resistance in breast cancer therapy
Nataliya Kutsevol, Yuliia Kuziv, Tetiana Bezugla, Pavlo Virych, Andrii Marynin, Tetiana Borikun, Natalia Lukianova, Petro Virych, Vasyl Chekhun
Applied Nanoscience. 2021;
[Pubmed] | [DOI]
125 Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies
Ana Cláudia Santos, Diana Costa, Laura Ferreira, Catarina Guerra, Miguel Pereira-Silva, Irina Pereira, Diana Peixoto, Nuno R. Ferreira, Francisco Veiga
Drug Delivery and Translational Research. 2021; 11(1): 49
[Pubmed] | [DOI]
126 Matrix Metalloproteinase-9-Responsive Surface Charge-Reversible Nanocarrier to Enhance Endocytosis as Efficient Targeted Delivery System for Cancer Diagnosis and Therapy
Qiu-Ju Han, Xiao-Tong Lan, Ying Wen, Chuan-Zeng Zhang, Michael Cleary, Yasra Sayyed, Guangdong Huang, Xiaoling Tuo, Long Yi, Zhen Xi, Lu-Yuan Li, Qiang-Zhe Zhang
Advanced Healthcare Materials. 2021; 10(9): 2002143
[Pubmed] | [DOI]
127 Multi-Functional Liposome: A Powerful Theranostic Nano-Platform Enhancing Photodynamic Therapy
Xiamin Cheng, Jing Gao, Yang Ding, Yao Lu, Qiancheng Wei, Dezhi Cui, Jiali Fan, Xiaoman Li, Ershu Zhu, Yongna Lu, Qiong Wu, Lin Li, Wei Huang
Advanced Science. 2021; 8(16): 2100876
[Pubmed] | [DOI]
128 Perspectives and controversies regarding the use of natural products for the treatment of lung cancer
Tingting Wen, Lei Song, Shucheng Hua
Cancer Medicine. 2021; 10(7): 2396
[Pubmed] | [DOI]
129 The Use of Phospholipids to Make Pharmaceutical Form Line Extensions
Peter Hoogevest, Harry Tiemessen, Josbert M. Metselaar, Simon Drescher, Alfred Fahr
European Journal of Lipid Science and Technology. 2021; 123(4): 2000297
[Pubmed] | [DOI]
130 Thymoquinone attenuates doxorubicin-cardiotoxicity in rats
Derya Karabulut, Emel Ozturk, Emin Kaymak, Ali Tugrul Akin, Birkan Yakan
Journal of Biochemical and Molecular Toxicology. 2021; 35(1)
[Pubmed] | [DOI]
131 Thymoquinone has a neuroprotective effect against inflammation, oxidative stress, and endoplasmic reticulum stress in the brain cortex, medulla, and hippocampus due to doxorubicin
Emin Kaymak, Ali Tugrul Akin, Emel Öztürk, Derya Karabulut, Nurhan Kuloglu, Birkan Yakan
Journal of Biochemical and Molecular Toxicology. 2021; 35(11)
[Pubmed] | [DOI]
132 A quantitative systems pharmacology approach to predict the safe-equivalent dose of doxorubicin in patients with cardiovascular comorbidity
Lan Sang, Yi Yuan, Ying Zhou, Zhengying Zhou, Muhan Jiang, Xiaoquan Liu, Kun Hao, Hua He
CPT: Pharmacometrics & Systems Pharmacology. 2021;
[Pubmed] | [DOI]
133 Ribosomal protein L5 mediated inhibition of c-Myc is critically involved in sanggenon G induced apoptosis in non-small lung cancer cells
Ji Eon Park, Ji Hoon Jung, Hyo-Jung Lee, Deok Yong Sim, Eunji Im, Woon Yi Park, Bum Sang Shim, Seong-Gyu Ko, Sung-Hoon Kim
Phytotherapy Research. 2021; 35(2): 1080
[Pubmed] | [DOI]
134 Advances in engineering local drug delivery systems for cancer immunotherapy
Peter Abdou, Zejun Wang, Qian Chen, Amanda Chan, Daojia R. Zhou, Vivienne Gunadhi, Zhen Gu
WIREs Nanomedicine and Nanobiotechnology. 2020; 12(5)
[Pubmed] | [DOI]
135 2D Germanane Derivative as a Vector for Overcoming Doxorubicin Resistance in Cancer Cells
Michaela Fojtu, Jan Balvan, Martina Raudenská, Tomáš Vicar, Jirí Šturala, Zdenek Sofer, Jan Luxa, Jan Plutnar, Michal Masarík, Martin Pumera
Applied Materials Today. 2020; 20: 100697
[Pubmed] | [DOI]
136 Protein phosphatase 1 in tumorigenesis: is it worth a closer look?
Juliana Felgueiras, Carmen Jerónimo, Margarida Fardilha
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2020; 1874(2): 188433
[Pubmed] | [DOI]
137 Preparation and in vitro/in vivo evaluation of doxorubicin-loaded poly[lactic-co-glycol acid] microspheres using electrospray method for sustained drug delivery and potential intratumoral injection
Ming-Yi Hsu, Yu-Ting Huang, Chun-Jui Weng, Chien-Ming Chen, Yong-Fong Su, Sung-Yu Chu, Jeng-Hwei Tseng, Ren-Chin Wu, Shih-Jung Liu
Colloids and Surfaces B: Biointerfaces. 2020; 190: 110937
[Pubmed] | [DOI]
138 Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells
Ujjwal Joshi, Nina Filipczak, Muhammad Muzamil Khan, Sara Aly Attia, Vladimir Torchilin
International Journal of Pharmaceutics. 2020; 590: 119915
[Pubmed] | [DOI]
139 Alginate microbeads with internal microvoids for the sustained release of drugs
Stefania Boi, Nadia Rouatbi, Elena Dellacasa, Donatella Di Lisa, Paolo Bianchini, Orietta Monticelli, Laura Pastorino
International Journal of Biological Macromolecules. 2020; 156: 454
[Pubmed] | [DOI]
140 Doxorubicin-loaded composite nanogels for cancer treatment
Marzieh Mohammadi, Leila Arabi, Mona Alibolandi
Journal of Controlled Release. 2020; 328: 171
[Pubmed] | [DOI]
141 In vitro irradiation of doxorubicin with 18F-FDG Cerenkov radiation and its potential application as a theragnostic system.
Hilda Angeline Quintos-Meneses, Liliana Aranda-Lara, Enrique Morales-Ávila, Eugenio Torres-García, Miguel Ángel Camacho-López, Mariana Sánchez-Holguín, Myrna A. Luna-Gutiérrez, Ninfa Ramírez-Durán, Keila Isaac-Olivé
Journal of Photochemistry and Photobiology B: Biology. 2020; 210: 111961
[Pubmed] | [DOI]
142 Arctigenin, a novel TMEM16A inhibitor for lung adenocarcinoma therapy
Shuai Guo, Yafei Chen, Sai Shi, Xuzhao Wang, Hailin Zhang, Yong Zhan, Hailong An
Pharmacological Research. 2020; 155: 104721
[Pubmed] | [DOI]
143 New molecular and biochemical insights of doxorubicin-induced hepatotoxicity
Pureti Lakshmi Prasanna, Kaviyarasi Renu, Abilash Valsala Gopalakrishnan
Life Sciences. 2020; 250: 117599
[Pubmed] | [DOI]
144 Graphene oxide as a potential drug carrier – Chemical carrier activation, drug attachment and its enzymatic controlled release
Anna Trusek, Edward Kijak, Ludomira Granicka
Materials Science and Engineering: C. 2020; 116: 111240
[Pubmed] | [DOI]
145 Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation
Marco Pirisinu, Tin Chanh Pham, Daniel Xin Zhang, Tran Nguyen Hong, Lap Thi Nguyen, Minh TN Le
Seminars in Cancer Biology. 2020;
[Pubmed] | [DOI]
146 Reversing P-Glycoprotein-Associated Multidrug Resistance of Breast Cancer by Targeted Acid-Cleavable Polysaccharide Nanoparticles with Lapatinib Sensitization
Junhui Sui, Mengmeng He, Yuedi Yang, Mengcheng Ma, Zhihao Guo, Mingda Zhao, Jie Liang, Yong Sun, Yujiang Fan, Xingdong Zhang
ACS Applied Materials & Interfaces. 2020; 12(46): 51198
[Pubmed] | [DOI]
147 Facile Fabrication Route of Janus Gold-Mesoporous Silica Nanocarriers with Dual-Drug Delivery for Tumor Therapy
Yang Xing, Ying Zhou, Yan Zhang, Caihong Zhang, Xu Deng, Chuan Dong, Shaomin Shuang
ACS Biomaterials Science & Engineering. 2020; 6(3): 1573
[Pubmed] | [DOI]
148 Effect of TAT-DOX-PEG irradiated gold nanoparticles conjugates on human osteosarcoma cells
Raoul V. Lupusoru, Daniela A. Pricop, Cristina M. Uritu, Adina Arvinte, Adina Coroaba, Irina Esanu, Mirela F. Zaltariov, Mihaela Silion, Cipriana Stefanescu, Mariana Pinteala
Scientific Reports. 2020; 10(1)
[Pubmed] | [DOI]
149 Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy
Wei Guo, Yuanyuan Song, Wantong Song, Yingmin Liu, Zhihe Liu, Dawei Zhang, Zhaohui Tang, Ou Bai
Scientific Reports. 2020; 10(1)
[Pubmed] | [DOI]
150 The implications of mitochondria in doxorubicin treatment of cancer in the context of traditional and modern medicine
Leonardo da Cunha Menezes Souza, Meng Chen, Yuji Ikeno, Daisy Maria Fávero Salvadori, Yidong Bai
Traditional Medicine and Modern Medicine. 2020; 03(04): 239
[Pubmed] | [DOI]
151 Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p
Xiaoxue Yu, Yang Ruan, Tao Shen, Quan Qiu, Mingjing Yan, Shenghui Sun, Lin Dou, Xiuqing Huang, Que Wang, Xiyue Zhang, Yong Man, Weiqing Tang, Zening Jin, Jian Li
BioMed Research International. 2020; 2020: 1
[Pubmed] | [DOI]
152 Protective Effect of miR-204 on Doxorubicin-Induced Cardiomyocyte Injury via HMGB1
Youyou Du, Guanghui Liu, Luosha Zhao, Rui Yao, Ding Sheng Jiang
Oxidative Medicine and Cellular Longevity. 2020; 2020: 1
[Pubmed] | [DOI]
153 Genomic instability and cancer: lessons from Drosophila
Stephan U. Gerlach, Héctor Herranz
Open Biology. 2020; 10(6): 200060
[Pubmed] | [DOI]
154 Doxorubicin delivery by polymer nanocarrier based on N-methylglucamine resorcinarene
Tatiana Yu. Sergeeva, Rezeda K. Mukhitova, Leysan R. Bakhtiozina, Irek R. Nizameev, Marsil K. Kadirov, Anastasia S. Sapunova, Alexandra D. Voloshina, Albina Y. Ziganshina, Igor S. Antipin
Supramolecular Chemistry. 2020; 32(2): 150
[Pubmed] | [DOI]
155 Development of stimuli-responsive intelligent polymer micelles for the delivery of doxorubicin
Fan Yang, Jiangkang Xu, Manfei Fu, Jianbo Ji, Liqun Chi, Guangxi Zhai
Journal of Drug Targeting. 2020; 28(10): 993
[Pubmed] | [DOI]
156 Reticulocalbin-1 knockdown increases the sensitivity of cells to Adriamycin in nasopharyngeal carcinoma and promotes endoplasmic reticulum stress-induced cell apoptosis
Ze-Hao Huang, Jun Qiao, Yi-Yang Feng, Meng-Ting Qiu, Ting Cheng, Jia Wang, Chao-Feng Zheng, Zhi-Qin Lv, Cai-Hong Wang
Cell Cycle. 2020; 19(13): 1576
[Pubmed] | [DOI]
157 Differential changes in the pharmacokinetics of doxorubicin in diethylnitrosamine-induced hepatocarcinoma model rats
Jie Pan, Yuan Lu, Shuai Zhang, Yueting Li, Jia Sun, Hua Chunhua Liu, Zipeng Gong, Jing Huang, Chuang Cao, Yonglin Wang, Yongjun Li, Ting Liu
Xenobiotica. 2020; 50(10): 1251
[Pubmed] | [DOI]
158 Pluronic P123 modified nano micelles loaded with doxorubicin enhanced tumor-suppressing effect on drug-resistant breast cancer cells
Xiaoyu Zhang, Weibin Chen, Jie Bai, Lijun Jin, Xiaoning Kang, Hui Zhang, Zunyi Wang
Aging. 2020; 12(9): 8289
[Pubmed] | [DOI]
159 Modification of graphene oxide by angiopep-2 enhances anti-glioma efficiency of the nanoscaled delivery system for doxorubicin
Yue Zhao, Hang Yin, Xiaoyu Zhang
Aging. 2020; 12(11): 10506
[Pubmed] | [DOI]
160 Preparation, characterization, and in vitro evaluation of amphiphilic peptide P12 and P12-DOX nanomicelles as antitumor drug carriers
Ping Song, Wuchen Du, Wanzhen Li, Longbao Zhu, Weiwei Zhang, Xinxing Gao, Yugui Tao, Fei Ge
Nanomaterials and Nanotechnology. 2020; 10: 1847980420
[Pubmed] | [DOI]
161 Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper
Nina Rosa Neuendorff, Kah Poh Loh, Alice S. Mims, Konstantinos Christofyllakis, Wee-Kheng Soo, Bediha Bölükbasi, Carlos Oñoro-Algar, William G. Hundley, Heidi D. Klepin
Blood Advances. 2020; 4(4): 762
[Pubmed] | [DOI]
162 Protective role of black seed oil in doxorubicin-induced cardiac toxicity in children with acute lymphoblastic leukemia
Adel A Hagag, Ibrahim M Badraia, Walid A El-Shehaby, Maaly M Mabrouk
Journal of Oncology Pharmacy Practice. 2020; 26(6): 1397
[Pubmed] | [DOI]
163 Galectin-3 inhibition attenuates doxorubicin-induced cardiac dysfunction by upregulating the expression of peroxiredoxin-4
Yunpeng Tian, Wei Lv, Chengzhi Lu, Yiyao Jiang, Xue Yang, Minghao Song
Canadian Journal of Physiology and Pharmacology. 2020; 98(10): 700
[Pubmed] | [DOI]
164 Tumor in 3D: In Vitro Complex Cellular Models to Improve Nanodrugs Cancer Therapy
Soraia Fernandes, Marco Cassani, Stefania Pagliari, Petr Filipensky, Francesca Cavalieri, Giancarlo Forte
Current Medicinal Chemistry. 2020; 27(42): 7234
[Pubmed] | [DOI]
165 Key Signaling Pathways Engaged in Cancer Management: Current Update
Sanjiv Singh, Rahul Shukla
Current Cancer Therapy Reviews. 2020; 16(1): 36
[Pubmed] | [DOI]
166 Drug Delivery Approaches for Doxorubicin in the Management of Cancers
Manish Vyas, Daniel A. Simbo, Mohd. Mursalin, Vijay Mishra, Roqia Bashary, Gopal L. Khatik
Current Cancer Therapy Reviews. 2020; 16(4): 320
[Pubmed] | [DOI]
167 Ditelluride-Bridged PEG-PCL Copolymer as Folic Acid-Targeted and Redox-Responsive Nanoparticles for Enhanced Cancer Therapy
Zekun Pang, Jiayan Zhou, Chunyang Sun
Frontiers in Chemistry. 2020; 8
[Pubmed] | [DOI]
168 Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity
Verena Schwach, Rolf H. Slaats, Robert Passier
Frontiers in Cardiovascular Medicine. 2020; 7
[Pubmed] | [DOI]
169 Krebs Cycle Intermediate-Modified Carbonate Apatite Nanoparticles Drastically Reduce Mouse Tumor Burden and Toxicity by Restricting Broad Tissue Distribution of Anticancer Drugs
Sultana Mehbuba Hossain, Syafiq Asnawi Zainal Abidin, Ezharul Hoque Chowdhury
Cancers. 2020; 12(1): 161
[Pubmed] | [DOI]
170 Signal transducer and activator of transcription 6 as a target in colon cancer therapy (Review)
Yael Delgado-Ramirez, Vaneesa Colly, Giovanni Villanueva Gonzalez, Sonia Leon-Cabrera
Oncology Letters. 2020; 20(1): 455
[Pubmed] | [DOI]
171 Assessing Advantages and Drawbacks of Rapidly Generated Ultra-Large 3D Breast Cancer Spheroids: Studies with Chemotherapeutics and Nanoparticles
Austin R. Holub, Anderson Huo, Kavil Patel, Vishal Thakore, Pranav Chhibber, Folarin Erogbogbo
International Journal of Molecular Sciences. 2020; 21(12): 4413
[Pubmed] | [DOI]
172 Liposomes for Intra-Articular Analgesic Drug Delivery in Orthopedics: State-of-Art and Future Perspectives. Insights from a Systematic Mini-Review of the Literature
Lucio Cipollaro, Paolo Trucillo, Nicola Luigi Bragazzi, Giovanna Della Porta, Ernesto Reverchon, Nicola Maffulli
Medicina. 2020; 56(9): 423
[Pubmed] | [DOI]
173 Liquid Chromatography–Tandem Mass Spectrometry for the Simultaneous Determination of Doxorubicin and its Metabolites Doxorubicinol, Doxorubicinone, Doxorubicinolone, and 7-Deoxydoxorubicinone in Mouse Plasma
Won-Gu Choi, Dong Kyun Kim, Yongho Shin, Ria Park, Yong-Yeon Cho, Joo Young Lee, Han Chang Kang, Hye Suk Lee
Molecules. 2020; 25(5): 1254
[Pubmed] | [DOI]
174 Doxorubicin Loaded Poloxamer Thermosensitive Hydrogels: Chemical, Pharmacological and Biological Evaluation
Chih Kit Chung, Jomarien García-Couce, Yaima Campos, Dana Kralisch, Katja Bierau, Alan Chan, Ferry Ossendorp, Luis Javier Cruz
Molecules. 2020; 25(9): 2219
[Pubmed] | [DOI]
175 Antitumor Features of Vegetal Protein-Based Nanotherapeutics
Silvia Voci, Agnese Gagliardi, Massimo Fresta, Donato Cosco
Pharmaceutics. 2020; 12(1): 65
[Pubmed] | [DOI]
176 The Basement Membrane in a 3D Breast Acini Model Modulates Delivery and Anti-Proliferative Effects of Liposomal Anthracyclines
Tabea Wiedenhoeft, Tobias Braun, Ronald Springer, Michael Teske, Erik Noetzel, Rudolf Merkel, Agnes Csiszár
Pharmaceuticals. 2020; 13(9): 256
[Pubmed] | [DOI]
177 Titanium Dioxide Nanoparticles: Prospects and Applications in Medicine
Daniel Ziental, Beata Czarczynska-Goslinska, Dariusz T. Mlynarczyk, Arleta Glowacka-Sobotta, Beata Stanisz, Tomasz Goslinski, Lukasz Sobotta
Nanomaterials. 2020; 10(2): 387
[Pubmed] | [DOI]
178 Toxicity of Carbon Nanomaterials and Their Potential Application as Drug Delivery Systems: In Vitro Studies in Caco-2 and MCF-7 Cell Lines
Rosa Garriga, Tania Herrero-Continente, Miguel Palos, Vicente L. Cebolla, Jesús Osada, Edgar Muñoz, María Jesús Rodríguez-Yoldi
Nanomaterials. 2020; 10(8): 1617
[Pubmed] | [DOI]
179 Design and Synthesis of Multi-Functional Superparamagnetic Core-Gold Shell Nanoparticles Coated with Chitosan and Folate for Targeted Antitumor Therapy
Sharafaldin Al-Musawi, Salim Albukhaty, Hassan Al-Karagoly, Faizah Almalki
Nanomaterials. 2020; 11(1): 32
[Pubmed] | [DOI]
180 Copolymacrolactones Grafted with l-Glutamic Acid: Synthesis, Structure, and Nanocarrier Properties
Ernesto Tinajero-Díaz, Antxon Martínez de Ilarduya, Sebastián Muñoz-Guerra
Polymers. 2020; 12(4): 995
[Pubmed] | [DOI]
181 Doxorubicin-Conjugated Iron Oxide Nanoparticles Synthesized by Laser Pyrolysis: In Vitro Study on Human Breast Cancer Cells
Iulia Ioana Lungu, Simona Nistorescu, Madalina Andreea Badea, Andreea-Mihaela Petre, Ana-Maria Udrea, Ana-Maria Banici, Claudiu Fleaca, Ecaterina Andronescu, Anca Dinischiotu, Florian Dumitrache, Angela Staicu, Mihaela Bala?
Polymers. 2020; 12(12): 2799
[Pubmed] | [DOI]
182 Extracts of Bridelia ovata and Croton oblongifolius induce apoptosis in human MDA-MB-231 breast cancer cells via oxidative stress and mitochondrial pathways
Juthathip Poofery, Bungorn Sripanidkulchai, Ratana Banjerdpongchai
International Journal of Oncology. 2020;
[Pubmed] | [DOI]
183 Low-intensity ultrasound enhances the antitumor effects of doxorubicin on hepatocellular carcinoma cells through the ROS-miR-21-PTEN axis
Chunhua Xia, Huabei Zeng, Yanfen Zheng
Molecular Medicine Reports. 2020;
[Pubmed] | [DOI]
184 MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition
Xiaoqing Guan, Shucheng Gu, Mu Yuan, Xiangxin Zheng, Ji Wu
Oncology Letters. 2019;
[Pubmed] | [DOI]
185 Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment
Steve Seung-Young Lee, Vytautas P. Bindokas, Stephen J. Kron
Molecular Cancer Therapeutics. 2019; 18(1): 213
[Pubmed] | [DOI]
186 Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice
Bryan Oronsky, Eilleen S. Y. Ao-Ieong, Ozlem Yalcin, Corey A. Carter, Pedro Cabrales
Molecular Pharmaceutics. 2019; 16(7): 2929
[Pubmed] | [DOI]
187 Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug
Simone A. Costa, Davoud Mozhdehi, Michael J. Dzuricky, Farren J. Isaacs, Eric M. Brustad, Ashutosh Chilkoti
Nano Letters. 2019; 19(1): 247
[Pubmed] | [DOI]
188 Phase-Change Material Packaged within Hollow Copper Sulfide Nanoparticles Carrying Doxorubicin and Chlorin e6 for Fluorescence-Guided Trimodal Therapy of Cancer
Qian Li, Lihong Sun, Mengmeng Hou, Qiubing Chen, Ruihao Yang, Lei Zhang, Zhigang Xu, Yuejun Kang, Peng Xue
ACS Applied Materials & Interfaces. 2019; 11(1): 417
[Pubmed] | [DOI]
189 pH-Responsive diblock copolymers made of ?-pentadecalactone and ionically charged a-amino acids
Ernesto Tinajero-Díaz, Antxon Martínez de Ilarduya, Sebastián Muñoz-Guerra
European Polymer Journal. 2019; 120: 109244
[Pubmed] | [DOI]
190 Cerium oxide nanoparticles: In pursuit of liver protection against doxorubicin-induced injury in rats
Heba G. Ibrahim, Noha Attia, Fatma El Zahraa A. Hashem, Moushira A.R. El Heneidy
Biomedicine & Pharmacotherapy. 2018; 103: 773
[Pubmed] | [DOI]
191 Photoresponsive Micelle-Incorporated Doxorubicin for Chemo-Photodynamic Therapy to Achieve Synergistic Antitumor Effects
Da Hye Kim, Hee Sook Hwang, Kun Na
Biomacromolecules. 2018; 19(8): 3301
[Pubmed] | [DOI]
192 Topoisomerases as anticancer targets
Justine L. Delgado, Chao-Ming Hsieh, Nei-Li Chan, Hiroshi Hiasa
Biochemical Journal. 2018; 475(2): 373
[Pubmed] | [DOI]
193 Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac
Thangirala Sudha, Dhruba J Bharali, Murat Yalcin, Noureldien HE Darwish, Melis Debreli Coskun, Kelly A Keating, Hung-Yun Lin, Paul J Davis, Shaker A Mousa
Nanomedicine. 2017; 12(3): 195
[Pubmed] | [DOI]
194 Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met
Yan Shu, Bo Xie, Zhen Liang, Jing Chen
Oncology Letters. 2017;
[Pubmed] | [DOI]
195 Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Rosie Elizabeth Ann Gutteridge, Mary Ann Ndiaye, Xiaoqi Liu, Nihal Ahmad
Molecular Cancer Therapeutics. 2016; 15(7): 1427
[Pubmed] | [DOI]
196 Heart failure and chemotherapeutic agents
Susan Piper, Theresa McDonagh
Future Cardiology. 2015; 11(4): 453
[Pubmed] | [DOI]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Abstract>Introduction>History of doxor...>Mechanism of act...>Doxorubicin in c...>Cardiotoxicity a...>Rationale for th...>Liposomal formul...>Pegylated liposo...>Nonpegylated lip...>Other novel form...>Conclusion>Article Figures>Article Tables
  In this article

 Article Access Statistics
    PDF Downloaded3038    
    Comments [Add]    
    Cited by others 196    

Recommend this journal